Collaborative Pharmaceutical Care Initiated in Hospital and Continued in Primary Care to Improve Medication Adherence of Patients With Rheumatoid Arthritis

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Rheumatoid arthritis (RA) is a public health issue because of its frequency, its functional consequences, the risk of morbidity and mortality and the costs incurred. A collaborative multiprofessional intervention initiated during hospitalization and continued after hospital discharge (ambulatory care ) would improve medication adherence in RA and therefore the health status of patients. Main objective: To compare, 12 months after the index hospitalization or consultation, the impact of pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician) on medication adherence to disease-modifying treatments of patients with RA compared to usual care without pharmaceutical care and specific multi-professional collaboration. Medication adherence to disease-modifying treatments will be assessed by the rate of coverage of disease-modifying treatments (or Medication Possession Ratio (MPR)). METHODOLOGY: Interventional, multicenter, controlled, randomized, open label study, comparing in parallel 2 groups of patients with rheumatoid arthritis initially hospitalized in a rheumatology department (pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician), initiated in the hospital and continued after hospital discharge (ambulatory care) vs traditional follow-up.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient with diagnosed rheumatoid arthritis (RA),

• Patient, male or female, aged 18 or over,

• Patient hospitalized or coming for a consultation in a rheumatology department, and returned home at hospital discharge

• Patient having DMARDs for RA (continuation or initiation) comprising at least methotrexate and/or a tsDMARD (targeted synthetic DMARD, JAK inhibitor) and/or subcutaneous bDMARD (biologic DMARD),

• Autonomous patient in the management of his drug treatment,

• Patient understanding and speaking French,

• Patient affiliated to the French general national health insurance or similar,

• Patient having given his free, informed and signed consent.

Locations
Other Locations
France
Service de rhumatologie et pathologie osseuse - Hôpital Edouard Herriot
RECRUITING
Lyon
Service de rhumatologie, Centre Hospitalier Lyon Sud, Groupement Hospitalier Sud, Hospices Civils de Lyon
NOT_YET_RECRUITING
Pierre-bénite
Contact Information
Primary
Roland CHAPURLAT, MD/PHD
roland.charpulat@chu-lyon.fr
04 72 11 74 82
Backup
Audrey JANOLY-DUMENIL, PharmD
audrey.janoly-dumenil@chu-lyon.fr
04 72 11 91 82
Time Frame
Start Date: 2022-06-28
Estimated Completion Date: 2027-12-28
Participants
Target number of participants: 200
Treatments
Experimental: Pharmaceutical care in multiprofessional collaboration
Medication reconciliation (hospital admission and discharge), disease-modifying antirheumatic drugs (DMARD) treatment information interview and 2 motivational interviews (after discharge, at 2 months and 6 months after the inclusion).
No_intervention: Control group (usual practices group)
Usual follow-up during the 12-month follow-up.
Related Therapeutic Areas
Sponsors
Leads: Hospices Civils de Lyon

This content was sourced from clinicaltrials.gov